Our Transactions
Leadership across the largest and most complex situations
Lead Financial Advisor
on its pending €8.0 billion
acquisition of
from Vodafone Group
2024
Exclusive Financial Advisor
on its pending ~$2.3 billion
acquisition of
2024
Independent Financial Advisor
on its pending acquisition of three fill-finish sites for an upfront payment of $11 billion from Novo Holdings following its $16.5 billion acquisition of Catalent
2024
Exclusive Financial Advisor
on its pending ~$35 billion
acquisition of
2024
Exclusive Financial Advisor
on its pending ~$12.6 billion
sale to
2024
Lead Financial Advisor
on its pending $11.5 billion
all-stock merger with
2024
Lead Financial Advisor
on its pending ~$13.4 billion
sale to
2023
Financial Advisor
on its pending ~$14.9 billion
sale to
2023
Financial Advisor
on its pending $60 billion
all-stock acquisition of
2023
Financial Advisor
on its up to $5.8 billion
acquisition of
2023
Financial Advisor
on its pending ~$20 billion
merger with
2023
Lead Left Bookrunner
$300 million
Follow-on Offering
2023
Exclusive Financial Advisor
on its chapter 11 restructuring of ~$1.9 billion of debt and $125 million DIP ABL financing
2023
Active Bookrunner
$1.1 billion IPO & $1.6 billion
Follow-on Offering
2023
Exclusive Financial Advisor
on its pre-packaged chapter 11 restructuring of ~$3.6 billion of debt and preferred equity
2023
Lead Financial Advisor
on its ~$36 billion
spin-off of
2021
Anouncement Date1
Status
Transaction
Value (M)
January 9, 2020
Closed
Advised lenders under the Nordic Facility in relation to the conclusion of the strategic partnership between CGG SA and Shearwater GeoServices Holding AS
NA
January 9, 2020
Closed
Advised Round Hill Capital on the sale of its shares in RESIDOMO, the largest privately held residential property portfolio in the Czech Republic
€1,300
January 8, 2020
Closed
Advised Oncoceutics on its sale to Chimerix
$438
January 8, 2020
Closed
Acted as an Active Bookrunner on the follow-on offering for Apellis Pharmaceuticals
$404
January 8, 2020
Closed
Acted as an Active Bookrunner on the follow-on offering for Mirum Pharmaceuticals
$48
January 7, 2020
Closed
Acted as a Joint Bookrunner on the follow-on offering for PNM Resources
$300
January 7, 2020
Closed
Advised AmeriLife Group, LLC on its growth investment from Thomas H. Lee Partners, L.P.
NA
January 7, 2020
Closed
Acted as an Active Bookrunner on the public common stock offering for Intra-Cellular Therapies
$295
1Announcement date for M&A transactions represents the date publicly announced; announcement date for restructurings represents the date publicly announced or filed; announcement date for capital markets transactions represents the pricing date.
« Previous 1 … 23 24 25